Immunoassay Controls and Validation: A Practical Guide to Analytical Quality

Immunoassays are analytical methods that use antibody-antigen reactions to measure analytes in biological samples. These methods underpin diagnostic testing for infectious diseases, autoimmune conditions, hormone disorders, and food safety screening. The reliability of any immunoassay result depends on two linked activities: the selection and use of appropriate controls during routine testing, and the formal validation of the assay before it enters routine service. This guide provides a practical framework for laboratory students, technicians, researchers, and diagnostic professionals who need to establish or verify analytical quality in immunoassay work. The focus is on concrete decisions: which controls to run, how to interpret validation parameters, what records to keep, and when to escalate problems to senior staff or seek external support.

Understanding Immunoassay Principles and Their Quality Implications

Immunoassays exploit the specificity of antibody-antigen binding to detect and quantify target molecules. The main formats include enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay, lateral flow immunoassay, radioimmunoassay, and enzyme-linked immunospot (ELISpot). Each format shares a common dependence on reagent quality, incubation conditions, washing steps, and signal detection. The Assay Guidance Manual from the National Center for Advancing Translational Sciences provides detailed technical guidance on assay design and execution across these formats.

The analytical quality of an immunoassay rests on several pillars. First, the antibody reagents must actually bind the intended target and not cross-react with related molecules. Second, the calibration system must produce a reliable relationship between signal and concentration. Third, the assay must perform consistently across runs, operators, and days. Fourth, the laboratory must have controls that detect when any of these elements fail.

Immunoassays can be classified as competitive or non-competitive. In a non-competitive immunoassay, also called a sandwich assay, the target analyte is captured by one antibody and detected by a second labeled antibody. This format is common for protein analytes such as hormones and cytokines. In a competitive immunoassay, the analyte in the sample competes with a labeled analyte for binding to a limited amount of antibody. This format is often used for small molecules such as drugs and steroids. The choice of format affects the design of controls and the interpretation of validation data.

The Laboratory Quality Management System Handbook from the World Health Organization emphasizes that quality control is a core component of laboratory operations. The handbook describes the components of a quality management system, including documentation, internal quality control, external quality assessment, and continuous improvement. For immunoassay laboratories, this means that control selection and validation activities must be documented, reviewed, and linked to corrective action procedures.

At a Glance: Control Selection and Validation Parameters

The table below summarizes the key decisions for control selection and validation parameters across common immunoassay types. Use this table as a starting point for assay planning and protocol review.

The Bioanalytical Method Validation Guidance from the U.S. Food and Drug Administration describes the standard parameters that should be evaluated during method validation. These include accuracy, precision, selectivity, sensitivity, reproducibility, and stability. The guidance applies to assays used in regulatory submissions but its principles are widely adopted across diagnostic and research laboratories.

Core Principles of Immunoassay Validation

Validation is the process of demonstrating that an assay performs reliably for its intended purpose. The Clinical Microbiology Reviews article on validation of laboratory-developed molecular assays notes that regulatory standards require clinical laboratories to establish and document their own performance specifications for laboratory-developed tests before implementation. The performance characteristics that must be established include accuracy, precision, reportable range, reference interval, analytical sensitivity, and analytical specificity.

Validation is not a single experiment but a structured program of studies. Each study addresses a specific performance question. The results are compared against pre-defined acceptance criteria. If the assay fails to meet any criterion, the laboratory must investigate the cause, modify the assay, and repeat the study. Validation is complete only when all acceptance criteria are met and the evidence is documented.

Analytical Sensitivity and Limit of Detection

Analytical sensitivity describes the ability of an assay to detect low concentrations of the target analyte. The limit of detection is the lowest concentration that can be distinguished from a blank sample with a stated level of confidence. The limit of quantification is the lowest concentration that can be measured with acceptable precision and accuracy.

The Journal of Pharmaceutical and Biomedical Analysis recommendations for anti-drug antibody immunoassays describe experimental approaches for establishing these parameters. For most immunoassays, the limit of detection is determined by running multiple replicates of a blank sample, calculating the mean signal and its standard deviation, and then determining the concentration corresponding to a signal that exceeds the blank by a defined margin.

Analytical Specificity and Cross-Reactivity

Analytical specificity is the ability of an assay to measure only the intended analyte without interference from other substances. Cross-reactivity occurs when antibodies bind to molecules that are structurally similar to the target analyte. This can produce false positive results or overestimate the true concentration.

The Autoimmunity article on anti-Scl-70 antibody testing illustrates the practical importance of specificity. The article notes that ELISAs for anti-Scl-70 antibodies are somewhat less specific than other techniques, especially in distinguishing patients with systemic sclerosis from those with other rheumatic diseases. This finding demonstrates that assay format and reagent choice directly affect clinical specificity. Laboratories must evaluate cross-reactivity against a panel of potentially interfering substances relevant to their sample types.

Precision and Reproducibility

Precision describes the closeness of agreement between repeated measurements of the same sample. Within-run precision, also called repeatability, measures variability when the same sample is tested multiple times in a single assay run. Between-run precision, also called intermediate precision, measures variability across different runs, operators, and days.

The Clinical Chemistry and Laboratory Medicine validation of a plasma GFAP immunoassay provides a recent example of precision evaluation. The study reported coefficients of variation for repeatability and intermediate precision below 12 percent. This level of precision was considered acceptable for the intended clinical use. The study also evaluated measurement range, interferences, and sample stability following Clinical and Laboratory Standards Institute guidelines.

Accuracy and Recovery

Accuracy describes how close the measured value is to the true concentration. For immunoassays, accuracy is often assessed through recovery studies. A known amount of analyte is spiked into a sample matrix, and the measured concentration is compared to the expected concentration. Recovery is expressed as a percentage of the expected value.

The Diagnostics article on analytical validation of an ELISA for maternal autoantibody-related autism describes a validation approach that included linearity, sensitivity, specificity, precision, and stability assessments. The study followed predefined validation protocols based on professional guidelines with established acceptance criteria for each parameter. This structured approach is recommended for any laboratory establishing a new immunoassay.

Linearity and Reportable Range

Linearity is the ability of an assay to produce results that are directly proportional to the concentration of the analyte in the sample. The reportable range is the span of concentrations over which the assay produces reliable results without dilution or concentration steps.

Linearity is typically assessed by diluting a high-concentration sample and comparing the measured values to the expected values. The Journal of Clinical Endocrinology and Metabolism study on IGF-I reference intervals demonstrates the importance of establishing method-specific reference intervals. The study developed and validated a new automated IGF-I immunoassay calibrated against a recommended international standard and established age- and sex-adjusted reference intervals from a large multicenter cohort.

Selecting and Implementing Analytical Controls

Controls are samples with known or expected results that are run alongside patient or test samples. Their purpose is to verify that the assay performed correctly in that particular run. A control result that falls outside the expected range signals that the run may be invalid and that patient results should not be reported.

Positive and Negative Controls

A positive control contains the target analyte at a known concentration. It verifies that the assay can detect the analyte and that the signal generation system is working. A negative control contains no target analyte. It verifies that the assay does not produce false positive signals and that the washing steps are effective.

The Nature Protocols article on a consensus platform for antibody characterization describes the use of knockout cell lines as controls for antibody validation. The platform uses isogenic knockout controls to systematically compare antibody performance in western blot, immunoprecipitation, and immunofluorescence. This approach provides a rigorous standard for confirming that an antibody binds its intended target and not other cellular proteins.

For immunoassays, the equivalent of a knockout control is a sample matrix that is known to lack the target analyte. This could be a pooled negative serum, a buffer blank, or a sample from a confirmed negative individual. The Methods in Molecular Biology chapter on ELISpot validation emphasizes that validation parameters must be interpreted in the context of the specific assay format and its intended use.

Calibration Curves and Standards

A calibration curve establishes the relationship between the measured signal and the analyte concentration. The curve is generated by running standards with known concentrations and fitting a mathematical model to the data. The choice of curve fit depends on the assay format and the concentration range.

Calibration standards must be prepared from a reference material with a known concentration. The Bioanalytical Method Validation Guidance describes the requirements for calibration standards, including the number of standards, the concentration range, and the acceptance criteria for back-calculated concentrations.

The Journal of Immunological Methods article on a semi-automated ELISA workflow demonstrates that internal controls can be monitored to ensure compliance with predefined acceptance criteria. The study compared manual and semi-automated workflows and found that internal controls for all plates met established acceptance ranges. This finding supports the use of internal controls as a routine quality check regardless of the level of automation.

Matrix Controls and Interference Checks

Matrix controls are samples that match the composition of the test samples but are known to be negative for the target analyte. They are used to detect matrix effects, where components of the sample interfere with the antibody-antigen reaction.

The Veterinary Sciences article on an indirect ELISA for porcine diarrhea-related Escherichia coli provides an example of matrix control use in a veterinary diagnostic setting. The optimized ELISA showed no detectable cross-reactivity with antibodies against other tested porcine pathogens and demonstrated good analytical sensitivity. The study also established a sample-to-positive ratio cutoff for interpreting field sera results.

Interference checks should include common interferents such as hemolysis, lipemia, and bilirubin. The Clinical Chemistry and Laboratory Medicine GFAP validation study found that GFAP concentrations were unaffected by hemolysis and remained stable under defined storage conditions. This type of information is essential for establishing sample acceptance criteria and handling procedures.

Practical Workflow for Assay Validation

The following workflow provides a structured approach to validating an immunoassay before routine use. Adapt the steps to your specific assay format and intended application.

Step 1: Define the Intended Use and Performance Requirements

Document the purpose of the assay, the sample types that will be tested, the expected concentration range, and the clinical or research decisions that will be based on the results. Define acceptance criteria for each validation parameter before starting the studies. The WHO Laboratory Quality Management System Handbook emphasizes that quality requirements must be defined before testing begins.

Step 2: Select and Characterize Reagents

Document the source, lot number, and storage conditions for all reagents including antibodies, standards, controls, and detection systems. If you are using a commercial kit, review the manufacturer documentation and verify that the kit is within its expiration date. If you are developing an in-house assay, characterize the antibodies for specificity and titer.

The Nature Communications article on insufficient antibody validation provides a cautionary example. The study rigorously validated 13 anti-oestrogen receptor beta antibodies and found that only one specifically targeted the intended protein in immunohistochemistry. This finding demonstrates that antibody validation failures can lead entire research fields astray. Laboratories must verify antibody performance instead of assume that commercial claims are accurate.

Step 3: Establish the Calibration Curve

Prepare standards across the expected concentration range and run them in replicate. Evaluate different curve fits and select the model that best describes the relationship between signal and concentration. Document the acceptance criteria for the curve, including the correlation coefficient and the back-calculated concentrations of the standards.

Step 4: Determine Sensitivity and Specificity

Run replicate blank samples to establish the limit of detection. Run samples with known concentrations to establish the limit of quantification. Test a panel of potentially cross-reacting substances to evaluate specificity. The Journal of Pharmaceutical and Biomedical Analysis recommendations describe experimental and statistical approaches for these validation studies.

Step 5: Evaluate Precision and Accuracy

Run multiple replicates of control samples at low, medium, and high concentrations across multiple days and operators. Calculate the within-run and between-run coefficients of variation. Perform recovery studies by spiking known amounts of analyte into sample matrices.

Step 6: Establish the Reportable Range and Reference Interval

Determine the range of concentrations over which the assay produces reliable results. If the assay will be used for diagnostic purposes, establish a reference interval using samples from an appropriate reference population. The Journal of Clinical Endocrinology and Metabolism IGF-I study demonstrates the importance of using large, well-characterized cohorts to construct robust reference ranges.

Step 7: Verify Sample Stability and Handling Requirements

Evaluate the stability of the analyte in samples under various storage conditions and freeze-thaw cycles. Document the acceptable time between collection and testing, the storage temperature, and any special handling requirements. The Clinical Chemistry and Laboratory Medicine GFAP study found that the analyte remained stable for up to 7 days at 4 degrees Celsius and under frozen storage conditions.

Step 8: Document the Validation Report

Prepare a validation report that summarizes the studies performed, the results obtained, and the acceptance criteria met. Include the final assay protocol, the control strategy, and the criteria for accepting or rejecting individual runs. The WHO Laboratory Quality Management System Handbook describes the documentation requirements for laboratory quality systems.

Records and Measurements for Ongoing Quality Monitoring

Once an assay is in routine use, the laboratory must maintain ongoing quality monitoring. This includes running controls with every batch, recording the results, and reviewing control trends over time.

Control Charts and Trend Analysis

Control results should be plotted on control charts that show the expected range and the actual results over time. A control result that falls outside the expected range indicates a problem with that run. A trend of increasing or decreasing control values, even within the expected range, may indicate reagent deterioration or instrument drift.

The Forensic Toxicology article in EXS emphasizes that analytical systems must be fully validated and fit for purpose, and that assay batches must be monitored with quality controls. The article also notes that external proficiency programs monitor both the assay and the personnel performing the work. Participation in external quality assessment schemes provides an independent check on assay performance.

Acceptance and Rejection Criteria

Define the criteria for accepting or rejecting a run before the run is performed. Typical criteria include the following: all control results must fall within their expected ranges, the calibration curve must meet the defined acceptance criteria, and the background signal must be within acceptable limits. If any criterion is not met, the run is rejected and patient results are not reported.

The PLOS ONE article on an integrated laboratory protocol for STI diagnosis describes a diagnostic workflow that includes internal and external quality assurance components, troubleshooting guidance, and recommendations for data management and sample traceability. The protocol is aligned with ISO 15189 and Clinical and Laboratory Standards Institute recommendations and is designed to be feasible in resource-limited laboratories.

Documentation Requirements

Maintain records of the following: reagent lot numbers and expiration dates, control results for each run, calibration curve parameters, instrument maintenance and calibration, operator training and competency assessments, and corrective actions taken when problems are identified. The WHO Laboratory Quality Management System Handbook provides detailed guidance on record keeping and document control.

Common Failure Patterns and Troubleshooting

Immunoassay failures can be grouped into several common patterns. Recognizing these patterns helps laboratories identify the root cause and implement corrective actions.

High Background Signal

A high background signal in negative controls or blank wells indicates non-specific binding or inadequate washing. Possible causes include the following: insufficient washing steps, contaminated reagents, incorrect blocking buffer, or antibody cross-reactivity. The troubleshooting approach is to check the washing protocol, verify reagent integrity, and evaluate the blocking conditions.

Low Signal in Positive Controls

A low signal in positive controls indicates that the assay is not detecting the analyte effectively. Possible causes include the following: degraded antibodies or standards, incorrect incubation times or temperatures, inactive detection reagents, or a problem with the substrate or chromogen. Check reagent expiration dates, verify incubation conditions, and confirm that the detection system is functioning.

Poor Precision Between Replicates

Poor precision between replicate wells indicates variability in the assay procedure. Possible causes include the following: inconsistent pipetting, uneven washing, temperature gradients across the plate, or edge effects. The troubleshooting approach is to review the pipetting technique, verify the plate washer function, and check the incubation conditions.

Calibration Curve Failures

A calibration curve that does not meet acceptance criteria may indicate problems with the standards, the curve fit, or the detection system. Check the standard preparation, verify the concentration of the stock standard, and review the curve fit model. The Bioanalytical Method Validation Guidance describes the acceptance criteria for calibration curves in regulated bioanalysis.

Matrix Effects and Interference

Unexpected results in patient samples may be caused by matrix effects or interfering substances. The Autoimmunity article on anti-Scl-70 testing notes that different assay techniques can produce different specificity profiles. If matrix effects are suspected, test the sample with a dilution series to check for parallelism, or test a spiked sample to evaluate recovery.

Hook Effect in Sandwich Assays

The hook effect occurs when very high concentrations of analyte saturate both the capture and detection antibodies, producing a falsely low signal. This is a particular risk in sandwich immunoassays for protein analytes. The Assay Guidance Manual describes strategies for detecting and avoiding the hook effect, including sample dilution and the use of two-step assay formats.

Biosafety and Regulatory Context

Immunoassay laboratories handle biological samples that may contain infectious agents. The WHO Laboratory Biosafety Manual provides guidance on safe handling of biological materials, including risk assessment, containment measures, and safe work practices. Laboratories must follow appropriate biosafety practices based on the risk group of the organisms that may be present in the samples.

The PLOS ONE article on integrated STI diagnosis describes a protocol that includes detailed pre-analytical requirements for blood collection, transport, and storage. These requirements are essential for both sample integrity and staff safety. Laboratories must have procedures for safe specimen handling, spill cleanup, and waste disposal.

Regulatory requirements for immunoassay validation vary by jurisdiction and application. Clinical laboratories in the United States must comply with the Clinical Laboratory Improvement Amendments, which require laboratories to establish and document performance specifications for laboratory-developed tests. The Clinical Microbiology Reviews article describes these requirements and the challenges laboratories face in meeting them.

For veterinary applications, the Veterinary Sciences article on porcine diarrhea ELISA demonstrates the application of validation principles to animal health diagnostics. The study established assay cutoff values and evaluated repeatability, reproducibility, and cross-reactivity in a veterinary context.

Professional Escalation Criteria

Laboratory staff should know when to escalate problems to senior personnel or seek external support. Escalate in the following situations: control results consistently fall outside the expected range despite troubleshooting, validation studies fail to meet acceptance criteria after protocol modifications, proficiency testing results indicate poor performance, or there is evidence of reagent or instrument failure that cannot be resolved locally.

The Forensic Toxicology article emphasizes that laboratories must understand the limitations of their analytical systems. If an assay is not performing reliably, the laboratory should stop reporting results and investigate the cause before resuming testing. Continuing to report results from an assay that is failing quality controls can lead to incorrect clinical decisions.

External support options include the following: contacting the reagent manufacturer for technical assistance, consulting published validation protocols, participating in external quality assessment schemes, and seeking advice from reference laboratories or professional organizations. The NCBI Literature Resources provide access to the scientific literature on immunoassay validation and troubleshooting.

Limitations of Immunoassay Validation

Validation demonstrates that an assay performs acceptably under defined conditions. It does not guarantee performance under all possible conditions. Laboratories must recognize the limitations of their validation studies and the ongoing need for quality monitoring.

Validation studies are typically performed with a limited number of samples and operators. The results may not fully represent the variability that will occur in routine use. The Journal of Pharmaceutical and Biomedical Analysis recommendations note that validation recommendations should be considered as examples of best practice instead of rigid requirements.

Reference intervals are population-specific and may not apply to all patient groups. The Journal of Clinical Endocrinology and Metabolism IGF-I study found that geographical region and sampling setting did not affect the reference intervals, but this may not hold for all analytes. Laboratories should verify reference intervals for their own patient populations when possible.

The Methods in Molecular Biology chapter on ELISpot validation notes that the validation of established protocols has been left to diverse opinions about how to interpret and tackle typical validation parameters. This highlights the need for laboratories to document their validation decisions and the rationale behind them.

Frequently Asked Questions

What is the difference between a positive control and a calibration standard?

A calibration standard is used to establish the relationship between signal and concentration across the assay range. A positive control is a sample with a known concentration that is run with each batch to verify that the assay performed correctly. Calibration standards generate the curve, while controls verify the curve is valid for that run.

How many replicates should I run for each control?

The number of replicates depends on the assay format and the precision requirements. For most immunoassays, running controls in duplicate or triplicate provides adequate confidence. The Bioanalytical Method Validation Guidance describes the number of replicates needed for validation studies, which may be higher than the number used for routine quality control.

What should I do if a control result falls outside the expected range?

Do not report patient results from that run. Investigate the cause before repeating the assay. Check reagent expiration dates, verify the control was prepared correctly, review the instrument function, and evaluate whether the problem is isolated to one control or affects the entire run. Document the investigation and the corrective action taken.

How often should I revalidate an immunoassay?

Revalidation is needed when there are significant changes to the assay, including new reagent lots, new equipment, changes to the protocol, or changes in the sample matrix. The Clinical Microbiology Reviews article notes that laboratories often modify approved assays and must establish performance specifications for the modified test.

What is the hook effect and how can I detect it?

The hook effect occurs in sandwich immunoassays when very high analyte concentrations saturate both antibodies, producing a falsely low signal. It can be detected by testing diluted samples and checking for parallelism. If the measured concentration increases with dilution, the hook effect may be present. The Assay Guidance Manual provides guidance on preventing and detecting this phenomenon.

How do I establish a cutoff value for a qualitative immunoassay?

A cutoff value separates positive from negative results. It is typically established by testing a panel of known positive and negative samples and selecting a threshold that optimizes sensitivity and specificity. The Veterinary Sciences article on porcine diarrhea ELISA provides an example of cutoff determination using a sample-to-positive ratio.

What is the difference between analytical sensitivity and clinical sensitivity?

Analytical sensitivity refers to the ability of the assay to detect low concentrations of the analyte. Clinical sensitivity refers to the ability of the test to identify individuals with the condition of interest. An assay can have excellent analytical sensitivity but poor clinical sensitivity if the analyte is not present in all affected individuals. The Autoimmunity article on anti-Scl-70 testing discusses the relationship between assay performance and clinical utility.

How do I validate an antibody for use in a new immunoassay?

Antibody validation should include specificity testing against the intended target and related molecules, titer determination, and performance testing in the intended assay format. The Nature Protocols article on antibody characterization describes a knockout cell line-based platform for systematic antibody comparison. The Nature Communications article on ER beta antibody validation demonstrates the consequences of inadequate antibody validation.

Related Diagnostic Guides

• BCA Assay Troubleshooting: Color Development and Compatibility Issues
• Multiplex Real-Time RT-PCR for Simultaneous Detection of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), Porcine Circovirus Type 2 (PCV2), and Swine Influenza A Virus (SIV) in Oral Fluids: Analytical Sensitivity, Specificity, and Field Validation
• Development and Validation of a CRISPR-Cas12a-Based Diagnostic Assay for Rapid Detection of African Swine Fever Virus in Porcine Samples
• Positive Controls in Western Blotting: Selection and Validation
• Understanding Positive and Negative Controls in Microbiology Experiments

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Validation of laboratory-developed molecular assays for infectious diseases.. Clinical microbiology reviews, 2010.
• Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.. Journal of pharmaceutical and biomedical analysis, 2008.
• Anti-scl-70.. Autoimmunity, 2005.
• Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.. The Journal of clinical endocrinology and metabolism, 2014.
• Forensic toxicology.. EXS, 2010.
• Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation.. Clinical chemistry and laboratory medicine, 2025.
• Important Considerations for ELISpot Validation.. Methods in molecular biology (Clifton, N.J.), 2024.
• A consensus platform for antibody characterization.. Nature protocols, 2025.
• Establishment of an Indirect ELISA Method for Detecting Multiple Virulence Factors from Porcine Diarrhea-Related &lt,i&gt,Escherichia coli&lt,/i&gt, Based on a Multi-Epitope Fusion Antigen.. 2026.
• A semi-automated ELISA workflow for SARS-CoV-2 Nucleocapsid IgG detection significantly improves throughput and reduces hands-on time.. 2026.
• Integrated laboratory protocol for the diagnosis of Sexually Transmitted Infections (STIs): Standardized pre-analytical procedures, rapid screening, hemagglutination, and ELISA methods for use in resource-limited settings.. 2026.
• Discovery of novel biomarkers associated with myocardial fibrosis in chimpanzees (Pan troglodytes)
• Analytical Validation of an ELISA Assay for Maternal Autoantibody-Related Autism.. 2026.
• Insufficient antibody validation challenges oestrogen receptor beta research. Nature Communications, 2017.
• Antibody Validation by Western Blotting.. Methods in molecular biology, 2017.
• Antibody Validation by Immunoprecipitation Followed by Mass Spectrometry Analysis.. Methods in molecular biology, 2017.
• Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods, 2014.
• Validation of screening methods according to Regulation 519/2014/EU. Determination of deoxynivalenol in wheat by lateral flow immunoassay: A case study. Trac Trends in Analytical Chemistry, 2016.
• Some validation considerations for immunoassays. Journal of Clinical Ligand Assay, 1997.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.